SVRA
Savara Inc Health Care Pharmaceutical Preparations Russell 3000
$4.82Close
$986.0MMarket cap
$3.95 – $6.9452-week range
Nov 11, 2026Next report
Highlights
Cautions
- Not in an uptrend 0 of 8 trend conditions
- Lagging the market RS 34 · weaker than 66% of stocks over 12 months
- Far from its high 31% below its 52-week high
- Results soon Nov 11, 2026, in 10 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
31%
1wk
up 14.2%
price change
1mo
down 6.6%
price change
12-month return
up 12%
market up 11% ·
its own 0%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
4.9×
price / book
Earnings yield
down 12.6%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 63%
return on equity
Free cash margin
—
-$101.1M FCF
D/E
0.15
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
5.8%
$0.28 a day · 2×ATR $4.26
RS
34 / 99
vs the universe
Trend
0 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
0.85
50 sessions
Implied move
—
no option chain · report Nov 11, 2026
Trend template · 0 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 18.6% over the year, from 172m to 205m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 6, 2020
Financials
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $257,000 | — | — | — | — | — |
| Operating income | -$49.3M | -$41.5M | -$38.8M | -$60.0M | -$103.2M | -$123.5M |
| Net income | -$49.6M | -$43.0M | -$38.1M | -$54.7M | -$95.9M | -$118.8M |
| Net margin | -19305% | — | — | — | — | — |
| Earnings per share | — | -$0.32 | -$0.25 | -$0.33 | -$0.48 | -$0.53 |
| Free cash flow | -$39.9M | -$40.1M | -$34.6M | -$51.4M | -$89.1M | -$101.1M |
| Free cash margin | -15519% | — | — | — | — | — |
| Cash | $22.9M | $34.0M | $52.1M | $26.6M | $15.1M | $33.2M |
| Long-term debt | $25.1M | $17.3M | $26.1M | $26.3M | $26.6M | $29.9M |
| Shareholders' equity | $64.4M | $144.5M | $107.8M | $140.4M | $171.4M | $203.1M |
| Shares outstanding | 54.15m | 114.04m | 114.05m | 138.14m | 172.42m | 204.57m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 11, 2026 | Quarterly ↗ | Jun 30, 2026 | 42d |
| May 12, 2026 | Quarterly ↗ | Mar 31, 2026 | 42d |
| Mar 13, 2026 | Annual ↗ | Dec 31, 2025 | 72d |
| Nov 12, 2025 | Quarterly ↗ | Sep 30, 2025 | 43d |
| Aug 13, 2025 | Quarterly ↗ | Jun 30, 2025 | 44d |
| May 13, 2025 | Quarterly ↗ | Mar 31, 2025 | 43d |
| Mar 27, 2025 | Annual ↗ | Dec 31, 2024 | 86d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 7, 2024 | Annual ↗ | Dec 31, 2023 | 67d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Jun 8, 2026 | Director or officer change · Charter or bylaws · Shareholder vote ↗ |
| Mar 13, 2026 | Material agreement ↗ |
| Jan 27, 2026 | Material agreement · New obligation ↗ |
| Jan 9, 2026 | Regulation FD ↗ |
| Oct 30, 2025 | Material agreement · Other events ↗ |
| Oct 29, 2025 | Material agreement · Regulation FD · Other events ↗ |
| Sep 2, 2025 | Regulation FD ↗ |
| Jun 6, 2025 | Shareholder vote ↗ |
| May 27, 2025 | Other events ↗ |
| Mar 31, 2025 | Agreement ended ↗ |
| Mar 26, 2025 | Material agreement · Agreement ended · New obligation · Regulation FD ↗ |
| Jan 23, 2025 | Director or officer change ↗ |